$Nuvation Bio (NUVB.US)$ 🤔 maybe a good buy??? 🚀🌟

$Nuvation Bio (NUVB.US)$
Can Nuvation Bio's Lung Cancer Drug Breakthrough Offset Rising R&D Costs?

$Nuvation Bio (NUVB.US)$ Nuvation Bio to Receive $150M in Royalty Interest Financing, $50M in Debt Upon FDA Approval of Taletrectinib by Sept 30 >NUVB
Dow Jones· 4 mins ago

$Nuvation Bio (NUVB.US)$ Item 1.01 Entry into a Material Definitive Agreement.
On March 3, 2025, Nuvation Bio Inc. (the “Company”) entered into a commercial supply agreement (the “Supply Agreement”) with Asymchem Laboratories (Tianjin) Co., Ltd. (“Asymchem”) to supply the Company with taletrectinib drug substance (the “Products”). Asymchem will be a non-exclusive supplier of the Products to the Company, and the Company will retain the right to procure the Products from one or more alternate...

$Nuvation Bio (NUVB.US)$
How Nuvation Bio's $250M Deal Could Transform Its Cancer Drug Launch Without Diluting Investors

$Nuvation Bio (NUVB.US)$ Reuters· just
Nuvation Bio Secures up to $250 Million in Non-Dilutive Financings From Sagard Healthcare Partners

nice one (: small but sweet.
$Nuvation Bio (NUVB.US)$

$Nuvation Bio (NUVB.US)$ Reuters· just1min
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer! June 23, 2025

$Nuvation Bio (NUVB.US)$
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
Nuvation Bio (NYSE: NUVB) announced positive pooled data from TRUST-I and TRUST-II studies evaluating taletrectinib, a next-generation ROS1 TKI for advanced ROS1-positive NSCLC. Key findings include:
- 89% tumor shr...

$Nuvation Bio (NUVB.US)$ big arse float but on watch